Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group
| العنوان: | Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group |
|---|---|
| المؤلفون: | Nora Muehlegger, Ursula Creutzig, Emma Steidel, Jan Stary, Dirk Reinhardt, Lucie Sramkova, Christiane Walter, Naghmeh Niktoreh, Nils von Neuhoff, Heidrun Boztug, Thomas Lehrnbecher, Jean-Pierre Bourquin, Michael Dworzak, Iveta Janotova, Mareike Rasche, Martin Zimmermann, Edward A. Kolb |
| المساهمون: | University of Zurich, Rasche, Mareike |
| المصدر: | Cancers, Vol 13, Iss 789, p 789 (2021) Cancers Volume 13 Issue 4 |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Acute promyelocytic leukemia, Pediatrics, medicine.medical_specialty, Down syndrome, Immunology, Population, Medizin, childhood acute myeloid leukemia, 610 Medicine & health, acute myeloid leukemia, Biochemistry, lcsh:RC254-282, Article, acute myeloid leukemia -- relapse -- childhood acute myeloid leukemia -- pediatric -- salvage therapy, Refractory, hemic and lymphatic diseases, medicine, Cumulative incidence, 1306 Cancer Research, ddc:610, salvage therapy, education, relapse, education.field_of_study, business.industry, Medizinische Fakultät » Universitätsklinikum Essen » Zentrum für Kinder- und Jugendmedizin » Klinik für Kinderheilkunde III, Myeloid leukemia, Cell Biology, Hematology, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Clinical trial, Regimen, pediatric, 10036 Medical Clinic, 2730 Oncology, business |
| الوصف: | Successful management of relapse is critical to improve outcomes of children with acute myeloid leukemia (AML). We evaluated response, survival and prognostic factors after a second relapse of AML. Among 1222 pediatric patients of the population-based AML-Berlin–Frankfurt–Munster (BFM) study group (2004 until 2017), 73 patients met the quality parameters for inclusion in this study. Central review of source documentation warranted the accuracy of reported data. Treatment approaches included palliation in 17 patients (23%), intensive therapy with curative intent (n = 46, 63%) and other regimens (n = 10). Twenty-five patients (35%) received hematopoietic stem cell transplantation (HSCT), 21 of whom (88%) had a prior HSCT. Survival was poor, with a five-year probability of overall survival (pOS) of 15 ± 4% and 31 ± 9% following HSCT (n = 25). Early second relapse (within one year after first relapse) was associated with dismal outcome (pOS 2 ± 2%, n = 44 vs. 33 ± 9%, n = 29 p < 0.0001). A third complete remission (CR) is required for survival: 31% (n = 14) of patients with intensive treatment achieved a third CR with a pOS of 36 ± 13%, while 28 patients (62%) were non-responders (pOS 7 ± 5%). In conclusion, survival is poor but possible, particularly after a late second relapse and an intensive chemotherapy followed by HSCT. This analysis provides a baseline for future treatment planning. |
| وصف الملف: | cancers-13-00789-v2.pdf - application/pdf; application/octet-stream; application/pdf |
| تدمد: | 2072-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90173760db6dc24a9f98249fddf7de1eTest https://pubmed.ncbi.nlm.nih.gov/33672815Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....90173760db6dc24a9f98249fddf7de1e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|